TScan is a clinical-stage biotechnology company dedicated to changing lives by developing safe and effective T-cell therapies for patients.
Our approach is based on the premise that conventional T cells provide the most effective way to fight cancer, and that by genetically reprogramming T cells with highly effective, naturally occurring T cell receptors (TCRs), we can harness the power of the human immune system to deliver life-changing therapies to patients.
We are advancing a robust pipeline of TCR-T therapy candidates derived from our proprietary platform to treat patients with heme malignancies and solid tumors
Our proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy.
We are committed to bringing new immunotherapies to cancer patients.
Partner at Baker Bros. Advisors LP
CFO of Nodthera
Chief Development Officer at Ichnos Sciences
Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
CEO of TSCAN
Former President of Pfizer Oncology
Former Chief Operating Officer of argenx
